Biosimilar monoclonal antibodies in China: A patent review-Reference-Cited by-同舟云学术

Biosimilar monoclonal antibodies in China: A patent review

Published:2022-06-01 Issue:6 Volume:13 Page:14503-14518
ISSN:2165-5979
Container-title:Bioengineered
language:en
Short-container-title:Bioengineered

Author:

Liu Jia-Wei¹²,Yang Yu-Huan¹²,Wu Nan¹^ORCID,Wei Ji-Fu¹³^ORCID

Affiliation:

1. Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

2. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China

3. Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21655979.2022.2090206

Reference117 articles.

1. The therapeutic monoclonal antibody market

2. The state-of-play and future of antibody therapeutics

3. Development of therapeutic antibodies for the treatment of diseases

5. FDA. FDA-approved biosimilar products. 2022.https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03

2. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events;Medical Oncology;2023-07-15

3. Biosimilars: Promising and Rapidly Emerging Biotherapeutics;Novel Technologies in Biosystems, Biomedical & Drug Delivery;2023